Lipid Panel with Ratios - NBI
Lipid Panel with Ratios - NBI

Lipid Panel with Ratios

Regular price $43.00

Heart disease is the number one killer of adults in the US. A lipid panel helps assess heart disease risk and is important because when you know your numbers you can take steps to reduce your risk. Lipids include cholesterol and triglycerides. There are two major types of cholesterol, called low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol.

Alternate Name(s): Cholesterol, HDL, Fasting Lipids, Cholesterol, LDL, Coronary Risk Panel

What’s Reported
  • Total Cholesterol
  • HDL Cholesterol
  • Triglycerides
  • LDL-Cholesterol (calculated)
  • Cholesterol/HDL Ratio (calculated)
  • LDL/HDL Ratio (calculated)
  • Non-HDL Cholesterol (calculated)

Methodology: Spectrophotometry (SP)

How to prepare

Fasting: Yes. Fast for 10-12 hours before taking this test.

Water: Drink plenty of water to stay hydrated.

Medications: Take all medications as prescribed.

Dietary supplements: Avoid dietary supplements the day of the test.

How long until you get the results

1-2 business days
Result turnaround times are estimates and not guaranteed. Due to factors outside of our control, such as weather, holidays, confirmation/repeat testing or equipment maintenance, our lab may require additional time to complete tests.

More about this test

Elevated LDL cholesterol and triglycerides are associated with increased heart disease risk. When too much low-density lipoprotein (LDL) circulates in the blood, it can slowly build up in the walls of the arteries that feed the heart and brain.

Together with other substances it can form plaque, a thick, hard deposit that can clog arteries. This condition is known as atherosclerosis. If a clot forms and blocks a narrowed artery, it can cause a heart attack or stroke.

In contrast, higher HDL cholesterol is associated with decreased heart disease risk. HDL cholesterol helps to transport cholesterol away from the arteries and back to the liver, where it is metabolized and removed from the body.

Low levels of high density lipoprotein (HDL) cholesterol are as much a risk factor for CAD as high LDL cholesterol. For these reasons, LDL cholesterol is sometimes referred to as “bad cholesterol” and HDL “good cholesterol.”

If your LDL cholesterol is high, bringing it down may decrease heart disease risk. Based on epidemiological data from the Framingham Offspring Study and the Munster Heart Study, it has been estimated that each one percent decrease in LDL cholesterol decreases the risk of major cardiovascular events by 1.0 to 1.5%. 

Since HDL cholesterol is associated with decreased cardiovascular disease risk, it’s not surprising that increasing HDL cholesterol is protective. Each 1 mg/dL increase in HDL cholesterol is associated with a 2%-3% decrease in CHD risk, even after adjustment for other risk factors, and predicts heart disease risk regardless of LDL levels.

Despite efforts by the medical and public health communities to increase awareness of the risks of poor lipid control and encourage lipid screening, patients often are inadequately treated, and less than 40% reach National Cholesterol Education Program (NCEP) low-density lipoprotein (LDL) cholesterol targets with monotherapy.

Testing your lipids and knowing your numbers is important for taking charge of your health and reducing your heart disease risk.

Related tests
Additional resources
References

Assmann, G., P. Cullen, and H. Schulte, The Munster Heart Study (PROCAM): results of follow-up at 8 years.Eur Heart J, 1998. 19(Suppl A): p. A2-A11.

Castelli, W.P., Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol, 1988. 4 Suppl A: p. 5A-10A.

Miller, M., Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc, 2003. 78(6): p. 735-42.

Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459-467.

Wilson, P.W., K.M. Anderson, and W.P. Castelli, Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham Offspring Study. Am J Med, 1991. 90: p. 11-16.